baclofen has been researched along with Fra(X) Syndrome in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Finally, the chronic administration of STX209 in juvenile mice corrected the increased spine density in Fmr1-knockout mice without affecting spine density in wild-type mice." | 1.38 | Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. ( Bear, MF; Brynczka, C; Carpenter, RL; Hammond, RS; Healy, AM; Henderson, C; Kind, PC; Kinoshita, MN; Paylor, R; Postma, FR; Rush, R; Shumway, M; Thomas, A; Vanderklish, PW; Warren, ST; Wijetunge, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Jonak, CR | 1 |
| Pedapati, EV | 1 |
| Schmitt, LM | 1 |
| Assad, SA | 1 |
| Sandhu, MS | 1 |
| DeStefano, L | 1 |
| Ethridge, L | 1 |
| Razak, KA | 1 |
| Sweeney, JA | 1 |
| Binder, DK | 1 |
| Erickson, CA | 1 |
| Zeidler, S | 1 |
| Pop, AS | 1 |
| Jaafar, IA | 1 |
| de Boer, H | 1 |
| Buijsen, RAM | 1 |
| de Esch, CEF | 1 |
| Nieuwenhuizen-Bakker, I | 1 |
| Hukema, RK | 1 |
| Willemsen, R | 1 |
| Straiker, A | 1 |
| Min, KT | 1 |
| Mackie, K | 1 |
| Qin, M | 1 |
| Huang, T | 1 |
| Kader, M | 1 |
| Krych, L | 1 |
| Xia, Z | 1 |
| Burlin, T | 1 |
| Zeidler, Z | 1 |
| Zhao, T | 1 |
| Smith, CB | 1 |
| Zhang, W | 1 |
| Xu, C | 1 |
| Tu, H | 1 |
| Wang, Y | 1 |
| Sun, Q | 1 |
| Hu, P | 1 |
| Hu, Y | 1 |
| Rondard, P | 1 |
| Liu, J | 1 |
| Pacey, LK | 1 |
| Tharmalingam, S | 1 |
| Hampson, DR | 1 |
| Hagerman, R | 1 |
| Lauterborn, J | 1 |
| Au, J | 1 |
| Berry-Kravis, E | 1 |
| Healy, A | 1 |
| Rush, R | 2 |
| Ocain, T | 1 |
| Berry-Kravis, EM | 1 |
| Hessl, D | 1 |
| Rathmell, B | 1 |
| Zarevics, P | 1 |
| Cherubini, M | 1 |
| Walton-Bowen, K | 1 |
| Mu, Y | 1 |
| Nguyen, DV | 1 |
| Gonzalez-Heydrich, J | 1 |
| Wang, PP | 1 |
| Carpenter, RL | 2 |
| Bear, MF | 2 |
| Hagerman, RJ | 1 |
| Henderson, C | 1 |
| Wijetunge, L | 1 |
| Kinoshita, MN | 1 |
| Shumway, M | 1 |
| Hammond, RS | 1 |
| Postma, FR | 1 |
| Brynczka, C | 1 |
| Thomas, A | 1 |
| Paylor, R | 1 |
| Warren, ST | 1 |
| Vanderklish, PW | 1 |
| Kind, PC | 1 |
| Healy, AM | 1 |
| Anagnostou, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neurophysiological and Acute Pharmacological Studies in FXS Patients[NCT02998151] | Early Phase 1 | 29 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Four 10-item lists of unrelated words were presented orally to the examinee who was then required to immediately recall words presented, at both pre-dose and post-dose timepoints. The impact of drug was assessed by subtracting the number of words remembered post-dose from the number of words remembered pre-dose. Lower numbers indicate more words remembered post-dose; higher numbers indicate more words remembered pre-dose. (NCT02998151)
Timeframe: Pre-dose, 4-hour post dose
| Intervention | number of words remembered (Mean) |
|---|---|
| Placebo | -.20 |
| Acamprosate | -1.47 |
| Lovastatin | -1.25 |
| Minocycline | -.69 |
| Baclofen | -.88 |
EEG relative gamma power at rest was calculated as the percent of power in the gamma frequencies relative to the sum of power in all frequency bands, averaged across electrodes, and calculated separately at pre-dose and post-dose timepoints. To assess the impact of drug, the pre-dose relative gamma power was subtracted from post-dose relative gamma power. Higher numbers indicate more relative gamma power post-dose; lower numbers indicate more relative gamma power pre-dose. (NCT02998151)
Timeframe: Pre-dose, 4-hour post-dose
| Intervention | percent of power in gamma frequencies (Mean) |
|---|---|
| Placebo | 0.0024 |
| Acamprosate | -0.0077 |
| Lovastatin | -0.0039 |
| Minocycline | 0.0019 |
| Baclofen | -0.0160 |
The Clinical Global Impressions - Improvement (CGI-I) requires the clinician to assess how much the patient's illness has changed relative to pre-dose, from 1 (very much improved) to 7 (very much worse). (NCT02998151)
Timeframe: 4-hour post-dose
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 3.70 |
| Acamprosate | 3.88 |
| Lovastatin | 3.97 |
| Minocycline | 3.81 |
| Baclofen | 3.94 |
Computerized task where an examinee is required to push a key when a target stimulus is presented on the screen. Scores are presented as change in median reaction time (RT), in milliseconds. (NCT02998151)
Timeframe: Predose, 4-hour post-dose
| Intervention | change in median RT in milliseconds (Mean) |
|---|---|
| Placebo | 13.76 |
| Acamprosate | -28.64 |
| Lovastatin | 18.59 |
| Minocycline | 26.85 |
| Baclofen | -31.44 |
Woodcock Johnson Test of Cognitive Abilities III Auditory Attention subscale. Participants must identify orally presented words amid increasingly intense background noise. The scores for this subtask range from 0-50, with higher scores indicating a better outcome. Raw scores for this subscale are reported (rather than standard scores, or age- or grade-equivalents). (NCT02998151)
Timeframe: 4-hour post-dose
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 32.84 |
| Acamprosate | 33.07 |
| Lovastatin | 32.93 |
| Minocycline | 33.24 |
| Baclofen | 33 |
2 reviews available for baclofen and Fra(X) Syndrome
| Article | Year |
|---|---|
Fragile X syndrome and targeted treatment trials.
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Baclofen; Brain-Derived Neurotrophic Factor; Central N | 2012 |
Fragile X syndrome: an update on developing treatment modalities.
Topics: Allosteric Regulation; Animals; Baclofen; Central Nervous System Agents; Drug Discovery; Fragile X S | 2011 |
1 trial available for baclofen and Fra(X) Syndrome
| Article | Year |
|---|---|
Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
Topics: Adolescent; Adult; Baclofen; Behavior; Child; Female; Fragile X Syndrome; Humans; Male; Nervous Syst | 2012 |
8 other studies available for baclofen and Fra(X) Syndrome
| Article | Year |
|---|---|
Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome.
Topics: Animals; Baclofen; Disease Models, Animal; Fragile X Mental Retardation Protein; Fragile X Syndrome; | 2022 |
Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.
Topics: Animals; Baclofen; Disease Models, Animal; Fragile X Mental Retardation Protein; Fragile X Syndrome; | 2018 |
Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons.
Topics: Adenosine; Animals; Baclofen; Data Interpretation, Statistical; Electrophysiological Phenomena; Exci | 2013 |
R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Topics: Animals; Baclofen; Behavior, Animal; Disease Models, Animal; Fragile X Mental Retardation Protein; F | 2015 |
GABAB receptor upregulates fragile X mental retardation protein expression in neurons.
Topics: Animals; Baclofen; Disease Models, Animal; Fragile X Mental Retardation Protein; Fragile X Syndrome; | 2015 |
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
Topics: Animals; Anticonvulsants; Baclofen; Benzamides; Blotting, Western; Cyclopentanes; Drug Interactions; | 2011 |
Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Topics: Animals; Baclofen; Behavior, Animal; Dendritic Spines; Disease Models, Animal; Drinking Water; Fragi | 2012 |
Translational medicine: Mice and men show the way.
Topics: Adolescent; Adult; Animals; Autistic Disorder; Baclofen; Child; Clinical Trials as Topic; Dendrites; | 2012 |